AB0859-HPR NETWORK OF SUPPORT AND DEPRESSION IN RHEUMATIC DISEASES
Authors: L. Cano Garcia, S. Manrique Arija, F. Godoy-Navarrete, F. G. Jiménez-Núñez, R. Redondo, N. Mena-Vázquez
Journal: Annals of the Rheumatic Diseases (2021)

Objectives: To describe the impact that depression has on the personal support network of patients with rheumatic diseases. Methods: Design. Cross-sectional observational study of a series of patients with spondyloarthritis (SpA), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) selected by consecutive sampling of the Rheumatology consultations. Selection criteria: age ≥18 years with AD (ASAS criteria), RA (EULAR / ACR 2010 criteria) and SLE (ACR-EULAR criteria) capable of understanding and willing to take the questionnaires. Protocol: The reference rheumatologist offered to participate in the study to all the patients who attended the consultation between October and December 2019 and met the selection criteria. After their approval and signing the informed consent, they went to the nursing consultation to carry out a battery of questionnaires from the PROMIS platform and collect clinical data. The infirmary was in charge of explaining the questionnaires to the patients. Variables: the main endpoint variable was depression evaluated by PROMIS and the secondary endpoint variables were questionnaires that evaluate the support network in various settings: company, emotional support, instrumental support, support through information. Likewise, data on their disease, comorbidities were collected using Charlson and socio-occupational profile. Statistical analysis: Descriptive analysis, R-Pearson correlation and multivariate linear regression analysis (VD: PROMIS depression). Results: 151 patients participated: 50 with RA (90% women, mean age 55.12 ± 13.64 years), 51 with AD (51% women, 52.59 ± 12.15 years) and 50 patients with SLE (96 % women, mean age 47.14 ± 11.3 years). The baseline characteristics and comorbidities of the included. The mean (SD) of PROMIS depression in all patients was 16.4 (8.3) and a total of 65 patients (43%) had depression according to the Charlson index. Patients with Charlson depression had a higher mean (SD) of PROMIS depression than those without Charlson depression (24.5 [6.2] vs 10.3 [2.5], p &lt;0.001). An inverse correlation was observed between PROMIS depression with the rest of PROMIS questionnaires: company (r = -0.369, p = &lt;0.001), emotional support (r = -0.533, p = &lt;0.001), information support (r = -0.577, p = &lt;0.001) and instrumental support (r = -0.362, p = &lt;0.001). Likewise, it was observed that patients without depression by Charlson compared with patients with depression had higher mean values (SD) in all questionnaires of the support network compared to those without depression by Charlson: company (17, 8 (2.9) vs 14.7 (4.7), p &lt;0.001), emotional support (37.2 (5.2) vs 29.0 (9.5), p &lt;0.001) and instrumental support (35.7 (7.2) vs 29.4 (8.8), p &lt;0.001).Finally, in the multivariate analysis, the variables that were independently associated with depression by PROMIS were information support (B = -0.390; p &lt;0.001) and emotional support (B = -0.239; p = 0.027). (R2 = 0.340). Conclusion: Depression in rheumatic diseases negatively influences the support network and the perception of company of these patients. Treating depression is important for social functioning and social relationships in these patients and for any group of chronic patients. Disclosure of Interests: None declared